|
Stem cell therapy in heart failure prevention and progress |
Brito V, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brito V, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Stem cell therapy in heart failure prevention and progress. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 478. 2016 Authors' conclusions In heart failure (HF) associated to remodeling and myocardial necrosis in acute myocardial infarction, evidence of moderate quality shows that stem cell therapy (SCT) does not decrease long term incidence or complications.
In HF secondary to chronic ischemic heart disease, evidence of low quality highlights a potential clinical benefit associated to SCT in terms of mortality and re-hospitalization, while evidence of moderate quality shows a mild improvement in the ejection fraction and functional class, although not clinically significant.
In non-ischemic HF, low quality evidence shows that SCT is associated with a slight improvement in ejection fraction, although not clinically significant.
The clinical practice guidelines and the consensus of experts identified consider it necessary to continue investigating the role of SCT in preventing and treating ischemic and non-ischemic HF.
In Argentina, INCUCAI (Instituto Nacional Central Único Coordinador de Ablación e Implante, National Unique Central Institute Coordinating Ablation and Implant) does not include SCT for the treatment of HF secondary to ischemic or non-ischemic heart disease.
The coverage policies identified consider TCM as experimental for the treatment of HF associated to ischemic and non-ischemic heart disease.
Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Cell- and Tissue-Based Therapy; Genetic Therapy; Heart Failure; Humans; Stem Cell Transplantation Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016001130 Date abstract record published 02/12/2016 |
|
|
|